Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of “Hold” from Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been given a consensus recommendation of “Hold” by the five analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $5.70.

Several research firms have recently weighed in on LXRX. Zacks Research cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Wall Street Zen lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Cantor Fitzgerald initiated coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, September 28th. They set an “overweight” rating and a $8.00 target price on the stock. Finally, Weiss Ratings raised shares of Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX opened at $1.82 on Monday. Lexicon Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $2.68. The company has a market capitalization of $809.83 million, a PE ratio of -12.13 and a beta of 1.07. The company has a debt-to-equity ratio of 0.29, a quick ratio of 13.29 and a current ratio of 13.37. The company has a fifty day moving average of $2.20 and a 200-day moving average of $2.05.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $0.69 million for the quarter, compared to analyst estimates of $3.99 million. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%. On average, equities analysts predict that Lexicon Pharmaceuticals will post -0.17 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at $28,000. CTC Alternative Strategies Ltd. bought a new position in shares of Lexicon Pharmaceuticals in the 1st quarter worth about $27,000. Bank of New York Mellon Corp lifted its stake in shares of Lexicon Pharmaceuticals by 43.6% in the 1st quarter. Bank of New York Mellon Corp now owns 27,459 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 8,335 shares during the period. WINTON GROUP Ltd boosted its position in shares of Lexicon Pharmaceuticals by 69.4% during the 2nd quarter. WINTON GROUP Ltd now owns 43,200 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 17,700 shares in the last quarter. Finally, AXQ Capital LP grew its stake in Lexicon Pharmaceuticals by 126.9% during the second quarter. AXQ Capital LP now owns 45,727 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 25,577 shares during the period. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for diseases with significant unmet medical needs. The company uses its expertise in human genetics and gene biology to identify novel drug targets and develop small-molecule therapies.

Lexicon’s marketed products include XERMELO (telotristat ethyl), an oral treatment for carcinoid syndrome diarrhea in adults whose symptoms are inadequately controlled by short-acting somatostatin analog therapy.